We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+23.65%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.28B
AUM Growth
+$464M
Cap. Flow
-$292M
Cap. Flow %
-5.53%
Top 10 Hldgs %
49.47%
Holding
185
New
37
Increased
47
Reduced
83
Closed
9

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$120M
2
FOLD
Amicus Therapeutics
FOLD
+$105M
3
NUVL
Nuvalent
NUVL
+$102M
4
KRYS icon
Krystal Biotech
KRYS
+$86.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$75.6M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$149M
2
INCY icon
Incyte
INCY
+$139M
3
AKRO
Akero Therapeutics
AKRO
+$113M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$109M
5
ARGX icon
argenx
ARGX
+$72.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Technology 0.1%
3 Consumer Discretionary 0.05%
4 Financials 0.03%
5 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSCO icon
126
Cisco
CSCO
$450B
$616K 0.01%
+8,000
New +$594K
CYTK icon
127
Cytokinetics
CYTK
$11B
$586K 0.01%
9,225
+7,125
+339% +$443K
ONC
128
BeOne Medicines Ltd
ONC
$33.8B
$574K 0.01%
1,890
-31,907
-94% -$10.4M
IWM icon
129
iShares Russell 2000 ETF
IWM
$80.9B
$566K 0.01%
2,300
– –
PG icon
130
Procter & Gamble
PG
$343B
$559K 0.01%
+3,900
New +$575K
META icon
131
Meta Platforms (Facebook)
META
$1.51T
$528K 0.01%
800
+400
+100% +$267K
DOCS icon
132
Doximity
DOCS
$3.67B
$523K 0.01%
11,817
+2,124
+22% +$119K
PTCT icon
133
PTC Therapeutics
PTCT
$6.37B
$514K 0.01%
6,763
+4,233
+167% +$308K
RPRX icon
134
Royalty Pharma
RPRX
$26.1B
$510K 0.01%
13,201
+240
+2% +$9.15K
V icon
135
Visa
V
$677B
$491K 0.01%
+1,400
New +$477K
BLK icon
136
Blackrock
BLK
$164B
$482K 0.01%
+450
New +$492K
INCY icon
137
Incyte
INCY
$23.5B
$471K 0.01%
4,773
-1,435,913
-100% -$139M
LULU icon
138
lululemon athletica
LULU
$13B
$465K 0.01%
+2,240
New +$406K
PLTR icon
139
Palantir
PLTR
$295B
$444K 0.01%
+2,500
New +$453K
ADBE icon
140
Adobe
ADBE
$89.5B
$420K 0.01%
+1,200
New +$408K
ACN icon
141
Accenture
ACN
$89.9B
$402K 0.01%
+1,500
New +$381K
CORT icon
142
Corcept Therapeutics
CORT
$10.2B
$365K 0.01%
10,495
+9,268
+755% +$728K
GRMN
143
Garmin
GRMN
$46.9B
$350K 0.01%
1,726
-305
-15% -$66.3K
PLNT icon
144
Planet Fitness
PLNT
$4.23B
$344K 0.01%
3,173
-1,128
-26% -$116K
EXEL icon
145
Exelixis
EXEL
$13.9B
$323K 0.01%
7,361
– –
JD icon
146
JD.com
JD
$40.8B
$316K 0.01%
+11,000
New +$344K
GH icon
147
Guardant Health
GH
$19.5B
$307K 0.01%
3,004
+1,051
+54% +$94K
SNY icon
148
Sanofi
SNY
$104B
$284K 0.01%
5,851
-3,009
-34% -$149K
TEM
149
Tempus AI
TEM
$7.69B
$282K 0.01%
4,776
-237
-5% -$18.5K
SMMT icon
150
Summit Therapeutics
SMMT
$10.9B
$249K ﹤0.01%
14,262
-4,720
-25% -$88.8K
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2025 Portfolio in Review

As of Q4 2025, Bellevue Group held 185 positions worth $5.28B, up 9.6% from $4.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $292M in Q4 2025, closing 9 positions and reducing 83 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Viridian Therapeutics worth $136M.

  • Bellevue Group's largest Q4 2025 buy was Viridian Therapeutics: 4,358,527 shares worth $136M.
  • Bellevue Group added most to Krystal Biotech in Q4 2025, an estimated $86.1M increase.
  • Bellevue Group's biggest Q4 2025 reduction was Incyte, cutting an estimated $139M.
  • Bellevue Group fully exited Agios Pharmaceuticals in Q4 2025, selling an estimated $149M.
  • Bellevue Group's ten largest holdings make up 49% of its $5.28B portfolio in Q4 2025.
  • Bellevue Group opened 37 new positions and closed 9 in Q4 2025.
  • Bellevue Group's portfolio value rose 9.6% quarter-over-quarter to $5.28B.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.